Pharmacological disease models
Small molecules and excitotoxic agents can be used to pharmacologically induce disease models such as epilepsy, Parkinson's Disease, catalepsy, Schizophrenia, pain and diabetes models. Researchers can save up to 50% on excitotoxic agents - they are up to half the price of other suppliers.
IWP 2 (HB0344)
Description:Potent Wnt pathway inhibitor and PORCN inhibitor. Suppresses R1 ESC self-renewal. Used in the production of cardiac organoids.
Purity:>98%
IWP 4 (HB3066)
Description:Potent Wnt/β-catenin signaling inhibitor. Induces cardiomyocyte differentiation of hESCs and iPSCs.
Purity:>98%
Jasplakinolide (HB3946)
Description:Cell permeable, non-fluorescent F-actin probe. Induces actin polymerization and stabilization.
Purity:>98%
JC-1 (HB0791)
Description:Mitochondrial membrane potential indicator/dye. Widely used in apoptosis studies.
Purity:>95%
JF-NP-26 (Caged-Raseglurant) (HB6127)
Description:Novel, inactive photocaged derivative of raseglurant which can be uncaged with violet light. Shows light-dependent analgesic activity in vivo.
Purity:>98%
JHU37152 (DREADD ligand) (HB6252)
Description:Novel DREADD agonist with high affinity and potency for hM3Dq and hM4Di. Active in vivo. Freebase.
Purity:>98%
- Description:
Novel DREADD agonist with high affinity and potency for hM3Dq and hM4Di. Active in vivo. Water soluble.
Purity:>98%